Pharmaceuticals
The FDA approved a subcutaneous starting dose of lecanemab, allowing Alzheimer's patients to begin treatment at home via weekly self-injection—removing a major access barrier to this disease-modifying therapy.
Biotechnology
The FDA's accelerated approval of Ultragenyx's Genglycos marks the first gene therapy for glycogen storage disease type Ia, signaling a new era in treating rare metabolic diseases at their genetic root.
Biotechnology
Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene has succeeded in its first Phase 3 trial in melanoma, marking the first late-stage win for any mRNA cancer vaccine and raising profound questions about the future of oncology and the mRNA platform itself.
Biotechnology
AstraZeneca discontinues Phase 3 trial of volrustomig, its PD-1/CTLA-4 bispecific antibody in lung cancer, revealing structural challenges in displacing Keytruda and diverging fortunes in the bispecific antibody race.
Biotechnology
Definium Therapeutics' Phase 3 Voyage trial shows DT120, a pharmaceutically optimized LSD formulation, achieved an 11.6-point reduction in anxiety scores—the strongest placebo-adjusted efficacy benefit ever observed in a pivotal GAD study.
Pharmaceuticals
Eli Lilly filed six lawsuits against black-market sellers of retatrutide on August 12, 2026. The legal action reveals a deeper structural tension in the obesity drug market that litigation alone cannot resolve.
Policy
Trump's executive order to reduce childhood vaccines from 17 to 11 raises critical questions about public health policy, pharmaceutical industry impacts, and the politicization of vaccine recommendations.
Biotechnology
Silence Therapeutics' Phase 2 SANRECO trial shows divesiran achieved an 88% clinical response rate in polycythemia vera patients, with quarterly dosing that could transform disease management for this rare blood disorder.
Policy
Senators Pete Ricketts and Elissa Slotkin have introduced the Biotech Investment National Security Act (BINSA), which would subject US-China pharmaceutical deals to federal scrutiny. The bipartisan bill signals a major shift in how Washington views biotech collaboration with China.
Pharmaceuticals
The FDA's approval of Orzeyful marks the first medicine to treat narcolepsy type 1 by directly restoring orexin signaling, representing a paradigm shift from symptom management to mechanism correction.
Biotechnology
LifeMine Therapeutics raised $263 million to develop LIFE-001, a next-generation calcineurin inhibitor designed to prevent organ rejection without the kidney damage caused by current immunosuppressants.
Pharmaceuticals
Today is the PDUFA decision date for Moderna's mFlusiva, the first mRNA-based seasonal flu vaccine ever to seek US approval. A unanimous 9-0 advisory panel vote, a 27% efficacy advantage over standard flu shots, and a dramatic regulatory reversal set the stage for a landmark decision.